Patents by Inventor Ulla Hansen

Ulla Hansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinolin-2(1H)-one inhibitors of Late SV40 Factor
    Patent number: 11458132
    Abstract: The present invention is directed to compositions, methods and kits for treatment of cancer, e.g., hepatocellular carcinoma (HCC). In some embodiments, the present invention discloses the use of a small-molecule compounds of Formula (I) to inhibit tubulin acetylation, to inhibit cell migration, or to modulate cell compaction.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: October 4, 2022
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott Edward Schaus, Ulla Hansen, Emily Ann York, Niranjana Pokharel
  • Late SV40 (LSF) inhibitors
    Patent number: 11420977
    Abstract: The present invention is directed to compositions, methods and kits for treatment of cancer, e.g. heptacellular carcinoma (HCC). In some embodiments, the present invention discloses the use of a small-molecule compounds of Formula (I)-(V) to inhibit tubulin methylation or to modulate chromatin or cytoskeleton modification in a cell.
    Type: Grant
    Filed: August 2, 2019
    Date of Patent: August 23, 2022
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott Edward Schaus, Ulla Hansen, Hang Gyeong Chin
  • HETEROCYCLIC LSF INHIBITORS AND THEIR USES
    Publication number: 20220112206
    Abstract: The present invention is directed to heterocyclic SV40 Factor (LSF) inhibitors and their uses. In some implementations, the present invention discloses small-molecule compounds of Formula (I). In some implementations, the compounds of Formula (I) are used in methods for inhibiting LSF in a subject. In some implementations, the compounds of Formula (I) are used in methods for treating cancer in a subject.
    Type: Application
    Filed: December 22, 2021
    Publication date: April 14, 2022
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott E. SCHAUS, Ulla HANSEN, John A. KAVOURIS, Emily A. YORK, Niranjana POKHAREL
  • QUINOLIN-2(1H)-ONE INHIBITORS OF LATE SV40 FACTOR
    Publication number: 20220062272
    Abstract: The present invention is directed to compositions, methods and kits for treatment of cancer, e.g., hepatocellular carcinoma (HCC). In some embodiments, the present invention discloses the use of a small-molecule compounds of Formula (I) to inhibit tubulin acetylation, to inhibit cell migration, or to modulate cell compaction.
    Type: Application
    Filed: September 1, 2021
    Publication date: March 3, 2022
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott Edward SCHAUS, Ulla HANSEN, Emily Ann YORK, Niranjana POKHAREL
  • Heterocyclic LSF inhibitors and their uses
    Patent number: 11242353
    Abstract: The present invention is directed to heterocyclic SV40 Factor (LSF) inhibitors and their uses. In some implementations, the present invention discloses small-molecule compounds of Formula (I). In some implementations, the compounds of Formula (I) are used in methods for inhibiting LSF in a subject. In some implementations, the compounds of Formula (I) are used in methods for treating cancer in a subject.
    Type: Grant
    Filed: January 22, 2021
    Date of Patent: February 8, 2022
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott E. Schaus, Ulla Hansen, John A. Kavouris, Emily A. York, Niranjana Pokharel
  • HETEROCYCLIC LSF INHIBITORS AND THEIR USES
    Publication number: 20210230173
    Abstract: The present invention is directed to heterocyclic SV40 Factor (LSF) inhibitors and their uses. In some implementations, the present invention discloses small-molecule compounds of Formula (I). In some implementations, the compounds of Formula (I) are used in methods for inhibiting LSF in a subject. In some implementations, the compounds of Formula (I) are used in methods for treating cancer in a subject.
    Type: Application
    Filed: January 22, 2021
    Publication date: July 29, 2021
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott E. SCHAUS, Ulla HANSEN, John A. KAVOURIS, Emily A. YORK, Niranjana POKHAREL
  • LATE SV40 (LSF) INHIBITORS
    Publication number: 20200039996
    Abstract: The present invention is directed to compositions, methods and kits for treatment of cancer, e.g. hepatocellular carcinoma (HCC). In some embodiments, the present invention discloses the use of a small-molecule compounds of Formula (I)-(V) to inhibit tubulin methylation or to modulate chromatin or cytoskeleton modification in a cell.
    Type: Application
    Filed: August 2, 2019
    Publication date: February 6, 2020
    Applicant: Trustees of Boston University
    Inventors: Scott Edward Schaus, Ulla Hansen, Hang Gyeong Chin
  • Inhibitors of Late SV40 Factor (LSF) as cancer chemotherapeutics
    Patent number: 10392398
    Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III?) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: August 27, 2019
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Ulla Hansen, Scott Schaus, Trevor Grant, Joshua Bishop, John Kavouris, Lisa M. Christadore
  • INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS
    Publication number: 20180051033
    Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III?) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.
    Type: Application
    Filed: September 25, 2017
    Publication date: February 22, 2018
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Ulla Hansen, Scott Schaus, Trevor Grant, Joshua Bishop, John Kavouris, Lisa M. Christadore
  • Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
    Patent number: 9815845
    Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III?) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: November 14, 2017
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Ulla Hansen, Scott Schaus, Trevor Grant, Joshua Bishop, John Kavouris, Lisa M. Christadore
  • Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
    Patent number: 9802948
    Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III?) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: October 31, 2017
    Assignee: TRUSTEES OF BOSTON UNIVERISTY
    Inventors: Ulla Hansen, Scott Schaus, Trevor Grant, Joshua Bishop, John Kavouris, Lisa M. Christadore
  • INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS
    Publication number: 20170107227
    Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III?) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.
    Type: Application
    Filed: December 23, 2016
    Publication date: April 20, 2017
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Ulla Hansen, Scott Schaus, Trevor Grant, Joshua Bishop, John Kavouris, Lisa M. Christadore
  • Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
    Patent number: 9597325
    Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formulas (I)-(XXVI) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: March 21, 2017
    Assignee: Trustees of Boston University
    Inventors: Ulla Hansen, Scott Schaus, Trevor Grant, Joshua Bishop, John Kavouris, Lisa M. Christadore
  • INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS
    Publication number: 20170044175
    Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formula (I)-(XXVI) and (III?) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.
    Type: Application
    Filed: October 28, 2016
    Publication date: February 16, 2017
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Ulla Hansen, Scott Schaus, Trevor Grant, Joshua Bishop, John Kavouris, Lisa M. Christadore
  • [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
    Patent number: 9399644
    Abstract: The present invention relates generally to methods, compounds and/or compositions suitable for inhibiting, preventing and/or treating cancer, e.g. hepatocellular carcinoma (HCC). In some embodiments, the invention relates to the use of small-molecule compounds to inhibit, prevent and/or treat expression of the transcription factor Late SV40 Factor (LSF) for treatment of HCC or other cancer types.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: July 26, 2016
    Assignee: Trustees of Boston University
    Inventors: Scott E. Schaus, Ulla Hansen, Joshua A. Bishop
  • [1,3] DIOXOLO [4,5-G] QUINOLINE-6(5H)THIONE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER
    Publication number: 20150344491
    Abstract: The present invention relates generally to methods, compounds and/or compositions suitable for inhibiting, preventing and/or treating cancer, e.g. hepatocellular carcionoma (HCC). In some embodiments, the invention relates to the use of small-molecule compounds to inhibit, prevent and/or treat expression of the transcription factor Late SV40 Factor (LSF) for treatment of HCC or other cancer types.
    Type: Application
    Filed: June 12, 2015
    Publication date: December 3, 2015
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott E. SCHAUS, Ulla HANSEN, Joshua A. BISHOP
  • [1,3] dioxolo [4,5-g] [1,2,4] triazolo [1,5-a] quinoline derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
    Patent number: 9175001
    Abstract: The present invention relates generally to [1,3]dioxolo[4,5-g]quinoline-6(5H)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives and/or compositions for use in inhibiting, preventing and/or treating cancer, e.g. hepatocellular carcionoma (HCC). In some embodiments, the invention relates to the use of small-molecule compounds to inhibit, prevent and/or treat expression of the transcription factor Late SV40 Factor (LSF) for treatment of HCC or other cancer types.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: November 3, 2015
    Assignee: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott E. Schaus, Ulla Hansen, Joshua A. Bishop
  • [1,3]DIOXOLO[4,5-G]QUINOLINE-6(5H)THIONE AND [1,3]DIOXOLO[4,5-G][1,2,4]TRIAZOLO[1,5-A]QUINOLINE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER
    Publication number: 20140249312
    Abstract: The present invention relates generally to [1,3]dioxolo[4,5-g]quinoline-6(5H)thione and [1,3]dioxolo[4,5-g][1,2,4]triazolo[1,5-a]quinoline derivatives and/or compositions for use in inhibiting, preventing and/or treating cancer, e.g. hepatocellular carcionoma (HCC). In some embodiments, the invention relates to the use of small-molecule compounds to inhibit, prevent and/or treat expression of the transcription factor Late SV40 Factor (LSF) for treatment of HCC or other cancer types.
    Type: Application
    Filed: October 12, 2012
    Publication date: September 4, 2014
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Scott E. Schaus, Ulla Hansen, Joshua A. Bishop
  • INHIBITORS OF LATE SV40 FACTOR (LSF) AS CANCER CHEMOTHERAPEUTICS
    Publication number: 20130324570
    Abstract: The present invention is directed to methods, compositions and kits for treatment of cancer, e.g. heptacellular carcinoma. In some embodiments, the present invention discloses the use of a small-molecule compound of formulas (I)-(XXVI) as disclosed herein to inhibit transcription factor Late SV40 Factor (LSF) for treatment of cancer, e.g., HCC.
    Type: Application
    Filed: September 30, 2011
    Publication date: December 5, 2013
    Applicant: TRUSTEES OF BOSTON UNIVERSITY
    Inventors: Ulla Hansen, Scott Schaus, Trevor Grant, Joshua Bishop, John Kavouris, Lisa M. Christadore